Medicamen Biotech Share Price Today (MEDICAMEQ)
TODAY IN ONE LINE
MEDICAMEQ fell 1.9% on light volume, lagging Nifty's -0.9% move, supported by recent strong earnings.
With a market cap of ₹328.22 Cr., it trades at a P/E of 32.07. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Medicamen Biotech flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 44.7% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 105.0% and Profit up 59.5%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 4.0%
- ●Rising Receivables vs SalesReceivables grew 19.2% outpacing sales growth of -9.3%
Latest Medicamen Biotech News
What changed recently?
Recent events, corporate actions, and announcements.
Medicamen Biotech Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Medicamen Biotech Limited, framed against the sector median so the premium or discount is obvious at a glance.
Medicamen Biotech Limited trades at a P/E of 32.07× and P/B of 1.12×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Medicamen Biotech Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Medicamen Biotech Limited — derived from the live tape, not yesterday's close.
Medicamen Biotech Limited last traded at ₹244.1 with an intraday range of ₹242.05–₹252.4 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹244.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 271.02 | +26.92 | +11.03% |
| R3 | 260.67 | +16.57 | +6.79% |
| R2 | 256.53 | +12.43 | +5.09% |
| R1 | 250.32 | +6.22 | +2.55% |
| PIVOT | 246.18 | 2.08 | 0.85% |
| CURRENT | 244.10 | — | — |
| S1 | 239.97 | -4.13 | -1.69% |
| S2 | 235.83 | -8.27 | -3.39% |
| S3 | 229.62 | -14.48 | -5.93% |
| S4 | 219.27 | -24.83 | -10.17% |
MEDICAMEQ is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹246.85–₹252.4
Trading Inside opening range
Medicamen Biotech Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Medicamen Biotech Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Medicamen Biotech Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹328.22 Cr. and reported EPS of ₹7.21.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 163 | 198 ▲ 21.7% |
| Sales Growth YoY %Derived | -9.35% | 21.67% |
| Other Income | 6 | 3 ▼ 50.1% |
| Total Income | 169 | 201 ▲ 19.0% |
| 85 | 102 ▲ 20.3% | |
| Gross ProfitDerived | 78 | 96 ▲ 23.2% |
| Gross Margin %Derived | 47.94% | 48.54% |
| 64 | 76 ▲ 19.3% | |
| EBITDA (Operating Profit)Derived | 14 | 20 ▲ 41.3% |
| OPM %Derived | 8.53% | 9.90% |
| 10 | 11 ▲ 4.8% | |
| Profit Before Tax (PBT) | 10 | 12 ▲ 21.3% |
| 3 | 2 ▼ 34.2% | |
| Effective Tax %Derived | 33.65% | 18.26% |
| Total Profit for Period | 7 | 10 ▲ 49.4% |
| Less: Non-controlling Interests | -1 | 0 ▲ 128.1% |
| Net Profit (Owner's PAT)Derived | 7 | 10 ▲ 35.6% |
| Net Profit Margin %Derived | 4.37% | 4.88% |
| PAT Growth YoY %Derived | -34.97% | 35.64% |
| Earnings Per Share (EPS ₹) | 5.59 | 7.11 ▲ 27.2% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 6.7% |
| Total Expenses (incl. D&A & Interest) | 159 | 189 ▲ 18.9% |
| Material Cost % of RevenueDerived | 55.77% | 47.71% |
| Employee Cost % of RevenueDerived | 19.61% | 17.54% |
| Other Cost % of RevenueDerived | 19.81% | 21.09% |
| Interest Coverage (x)Derived | 2.15x | 3.54x |
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 126 | 113 ▼ 10.2% | 115 ▲ 2.4% | 141 ▲ 22.0% | 179 ▲ 27.3% | 163 ▼ 9.3% | 198 ▲ 21.7% | |
| Sales Growth YoY %Derived | — | -10.19% | 2.42% | 22.02% | 27.29% | -9.35% | 21.67% | |
| Other Income | 2 | 1 ▼ 61.1% | 2 ▲ 128.1% | 2 ▲ 43.1% | 2 ▼ 5.5% | 6 ▲ 168.5% | 3 ▼ 50.1% | |
| Total Income | 127 | 113 ▼ 11.0% | 117 ▲ 3.3% | 143 ▲ 22.3% | 182 ▲ 26.7% | 169 ▼ 7.1% | 201 ▲ 19.0% | |
79 | 69 ▼ 12.0% | 52 ▼ 24.6% | 72 ▲ 37.7% | 93 ▲ 28.4% | 85 ▼ 8.6% | 102 ▲ 20.3% | ||
| Gross ProfitDerived | 47 | 43 ▼ 7.1% | 63 ▲ 45.9% | 69 ▲ 9.0% | 87 ▲ 26.1% | 78 ▼ 10.1% | 96 ▲ 23.2% | |
| Gross Margin %Derived | 37.12% | 38.38% | 54.65% | 48.82% | 48.36% | 47.94% | 48.54% | |
27 | 24 ▼ 12.5% | 40 ▲ 64.6% | 45 ▲ 13.5% | 64 ▲ 43.6% | 64 ▼ 0.6% | 76 ▲ 19.3% | ||
| EBITDA (Operating Profit)Derived | 19 | 19 ▲ 0.6% | 24 ▲ 22.5% | 24 ▲ 1.4% | 22 ▼ 6.8% | 14 ▼ 37.7% | 20 ▲ 41.3% | |
| OPM %Derived | 15.23% | 17.05% | 20.40% | 16.95% | 12.40% | 8.53% | 9.90% | |
3 | 4 ▲ 16.8% | 7 ▲ 100.1% | 9 ▲ 29.5% | 11 ▲ 23.7% | 10 ▼ 11.0% | 11 ▲ 4.8% | ||
| Profit Before Tax (PBT) | 18 | 16 ▼ 8.8% | 18 ▲ 10.4% | 17 ▼ 5.8% | 13 ▼ 23.3% | 10 ▼ 24.4% | 12 ▲ 21.3% | |
5 | 4 ▼ 9.1% | 3 ▼ 25.0% | 2 ▼ 27.5% | 4 ▲ 54.6% | 3 ▼ 7.2% | 2 ▼ 34.2% | ||
| Effective Tax %Derived | 26.08% | 26.01% | 17.67% | 13.59% | 27.39% | 33.65% | 18.26% | |
| Total Profit for Period | 13 | 12 ▼ 8.7% | 15 ▲ 22.8% | 15 ▼ 1.1% | 9 ▼ 35.5% | 7 ▼ 30.9% | 10 ▲ 49.4% | |
| Less: Non-controlling Interests | — | — | — | -0 | -1 ▼ 1143.1% | -1 ▲ 61.6% | 0 ▲ 128.1% | |
| Net Profit (Owner's PAT)Derived | 13 | 12 ▼ 8.7% | 15 ▲ 22.8% | 15 ▼ 0.4% | 11 ▼ 26.4% | 7 ▼ 35.0% | 10 ▲ 35.6% | |
| Net Profit Margin %Derived | 10.59% | 10.76% | 12.90% | 10.54% | 6.10% | 4.37% | 4.88% | |
| PAT Growth YoY %Derived | — | -8.74% | 22.82% | -0.36% | -26.36% | -34.97% | 35.64% | |
| Earnings Per Share (EPS ₹) | 10.88 | 9.93 ▼ 8.7% | 12.19 ▲ 22.8% | 11.73 ▼ 3.8% | 8.64 ▼ 26.3% | 5.59 ▼ 35.3% | 7.11 ▲ 27.2% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 3.6% | 1 ▲ 0.0% | 1 ▲ 0.5% | 1 ▲ 6.7% | |
| Total Expenses (incl. D&A & Interest) | 109 | 97 ▼ 11.3% | 99 ▲ 2.1% | 126 ▲ 27.5% | 169 ▲ 33.5% | 159 ▼ 5.7% | 189 ▲ 18.9% | |
| Material Cost % of RevenueDerived | 64.10% | 60.70% | 48.24% | 58.07% | 58.39% | 55.77% | 47.71% | |
| Employee Cost % of RevenueDerived | 7.59% | 7.99% | 12.56% | 14.51% | 16.77% | 19.61% | 17.54% | |
| Other Cost % of RevenueDerived | 14.30% | 13.33% | 21.69% | 17.36% | 19.19% | 19.81% | 21.09% | |
| Interest Coverage (x)Derived | 29.22x | 15.70x | 12.69x | 5.99x | 3.44x | 2.15x | 3.54x |
Medicamen Biotech segment analysis : revenue and profit mix.
Disclosed business segments at Medicamen Biotech with their share of revenue and profit, switchable between consolidated and standalone reporting.
Medicamen Biotech discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Medicamen Biotech Limited.
Our AI distills the core fundamental drivers supporting Medicamen Biotech Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Medicamen Biotech Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 107% YoY, demonstrating strong earnings acceleration momentum.
TTM EPS grew 44.7% YoY, showing sustained profitability improvement over trailing twelve months.
Low debt-to-equity ratio of 0.0017 indicates exceptional solvency and financial stability.
Vertically integrated business model provides control over quality, cost, and time-to-market.
Diversified therapeutic portfolio across oncology, cardiology, CNS, diabetology reduces concentration risk.
Key Risks.
Operating margin of 6.25% significantly lags industry peers, indicating weak pricing power.
Negative operating cash flow of ₹124.06 Cr in latest quarter signals severe liquidity concerns.
ROE of 3.95% and ROCE of 5.43% far below peer medians, reflecting poor capital efficiency.
Quarterly sales flat at 0% YoY despite TTM revenue growth, showing inconsistent top-line momentum.
Persistent negative free cash flow of ₹145.81 Cr limits reinvestment and strategic flexibility.
Flip Conditions.
Valuation risk. a P/E above 42 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Medicamen Biotech Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Medicamen Biotech Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Medicamen Biotech Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Medicamen Biotech Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Medicamen Biotech Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Medicamen Biotech Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Medicamen Biotech Limited stood at 60.9% of traded volume, against a 20-day average of 63.4%.
Medicamen Biotech announcements: results, concalls, ratings, M&A.
Filings Medicamen Biotech sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Medicamen Biotech files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 30 documents below.
Trading Window
Medicamen Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Statement of deviation(s) or variation(s) under Reg. 32
Medicamen Biotech Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
Copy of Newspaper Publication
Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Disclosure of material issue
Medicamen Biotech Limited has informed regarding Disclosure of material issue
Medicamen Biotech dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Medicamen Biotech has declared, sequenced by announce and record date.
Medicamen Biotech corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Medicamen Biotech Limited: business, sector, key facts.
What Medicamen Biotech Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Medicamen Biotech Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MEDICAMEQ, BSE: 531146.
Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is a fully integrated pharmaceutical company with a global reach. Its business model encompasses the entire pharmaceutical value chain, from initial research and development to the final marketing, sales, and distribution of its products. This vertical integration allows for greater control over quality, cost, and time-to-market for its diverse range of pharmaceutical formulations.
Medicamen's product portfolio is extensive and caters to a broad spectrum of therapeutic areas. The company manufactures and sells medications in various forms, including tablets, capsules, oral solutions, and drops. These formulations address critical health needs across multiple therapeutic categories such as oncology (cancer care), cardiology (heart health), central nervous system (CNS) disorders, diabetology (diabetes management), infectious diseases (anti-infectives), antimalarial treatments, vitamins and supplements, other generic medications, and pain management. This diversification minimizes reliance on any single therapeutic area and allows for greater market stability.
The company's operational footprint extends both domestically within India and internationally, signifying a commitment to serving patients globally. While specific details about its international market penetration are not provided, the mention of international distribution indicates a significant presence beyond its home market. This global reach enhances the company's revenue streams and potentially mitigates risks associated with dependence on a single geographic region.
In summary, Medicamen Biotech Limited is a well-established pharmaceutical company with a vertically integrated business model. Its diverse product portfolio, spanning numerous therapeutic areas and dosage forms, coupled with its domestic and international distribution network, positions it as a significant player in the pharmaceutical industry. The company's long history and comprehensive approach to pharmaceutical production and distribution suggest a robust and sustainable business model.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Medicamen Biotech Limited (MEDICAMEQ).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Medicamen Biotech Limited (MEDICAMEQ)?
The current share price of Medicamen Biotech Limited (MEDICAMEQ) is ₹244.1. Today, the stock has declined by ₹4.80 (1.93%), trading in a range of ₹242.05 to ₹252.4. The stock opened at ₹247.5 with a trading volume of 11,003 shares.
02Is Medicamen Biotech Limited stock a good investment for long-term?
Medicamen Biotech Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹328.22 crores, P/E ratio of 32.07, ROE of 3.95%, and ROCE of 5.43%. The dividend yield stands at 0.41%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Medicamen Biotech Limited stock?
The 52-week high price of Medicamen Biotech Limited (MEDICAMEQ) is ₹447.65, while the 52-week low is ₹212.4. Currently trading at ₹244.1, the stock is 13.5% away from its 52-week low and 45.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Medicamen Biotech Limited stock at the current price?
Whether to buy Medicamen Biotech Limited stock at ₹244.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 32.07 and P/B ratio of 1.12. Today's performance shows a loss of 1.93%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Medicamen Biotech Limited and when is the next dividend?
Medicamen Biotech Limited offers a dividend yield of 0.41%, which means for every ₹100 invested at the current price of ₹244.1, you can expect to receive approximately ₹0.41 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Medicamen Biotech Limited?
Medicamen Biotech Limited's key financial metrics include: P/E Ratio: 32.07, P/B Ratio: 1.12, ROE: 3.95%, ROCE: 5.43%, Dividend Yield: 0.41%, EPS: ₹7.21, Book Value: ₹234.32, and Debt-to-Equity: 0.17. The company's market cap stands at ₹328.22 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Medicamen Biotech Limited stock performing today in the market?
Medicamen Biotech Limited stock opened at ₹247.5 and is currently trading at ₹244.1, showing a decline of ₹4.80 (1.93%). The intraday high is ₹252.4 and low is ₹242.05. The trading volume stands at 11,003 shares, indicating moderate market participation today.
08What is the P/E ratio of Medicamen Biotech Limited and what does it indicate?
Medicamen Biotech Limited has a Price-to-Earnings (P/E) ratio of 32.07, which means investors are willing to pay ₹32.07 for every ₹1 of earnings. With an EPS of ₹7.21, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Medicamen Biotech Limited (MEDICAMEQ) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.